-
2025-522377-12-00
5
metastatic colorectal cancer
-
2025-522855-25-00
5
Carcinoma, Transitional Cell
-
2025-521314-25-00
5
2026-03-19
NPM1-m and KMT2A-r Acute Myeloid Leukemia
-
2024-512423-36-00
5
2024-11-20
Undifferentiated pleomorphic sarcoma
-
2023-507402-13-00
5
2024-04-03
Multiple myeloma
-
2023-507518-28-00
5
2022-09-13
Acute myeloid leukemia
-
2023-506414-46-00
5
2022-04-22
High risk patients defined as having at least one of the following ris
-
2024-520101-39-00
5
2026-04-01
TROP2 NMR-positive advanced or metastatic non-squamous non-small cell
-
2024-519929-38-00
4
2025-10-27
Metastatic Colorectal Cancer without liver metastases
-
2024-517780-24-00
5
2025-09-18
Lung Cancer
-
2024-514030-20-00
4
2025-08-29
colorectal cancer
-
2024-512583-57-00
5
2025-07-30
HER2-positive locally advanced or metastatic gastric or gastroesophage
-
2023-508507-20-00
5
2025-04-03
Locally advanced or metastatic conventional chondrosarcoma with an IDH
-
2023-508076-11-00
5
2025-04-01
Colon cancer staged T3-4 and/or nodal positive by CT and/or MRI scan w
-
2024-517966-40-00
4
2023-07-13
Acute lymphoblastic leukemia (ALL), de novo, Ph/BCR::ABL1 positive (Ph
-
2023-507557-16-00
5
2022-08-31
chronic myelogenous leukemia (CML) or Philadelphia Chromosome positive
-
2022-501180-40-00
5
2022-06-17
Ewing Sarcoma
-
2024-512174-10-00
5
2021-11-11
metastatic colorectal cancer
-
2024-516392-33-00
5
2021-09-17
Patients (18-75 years) with metastatic and/or refractory soft-tissue
s
-
2024-513621-23-00
5
2025-04-18
Advanced/metastatic non-small cell lung cancer (NSCLC)
-
2022-502975-45-00
5
2023-12-12
Metastatic leiomyosarcoma
-
2024-515224-37-00
4
2023-08-29
Patients with MSI-high or MMR-deficient stage III colorectal cancer wh
-
2024-512980-29-00
4
2023-08-28
T1-T2N0 esophageal adenocarcinoma including gastroesophageal
junction
-
2022-500637-80-00
5
2023-03-28
gastrointestinal stromal tumor